TENAX THERAPEUTICS, INC. short interest in 2019
In 2019, TENAX THERAPEUTICS, INC.'s disclosed short interest ran from 2.93% of shares outstanding on 15 Jan 2019 to 0.92% on 31 Dec 2019, a change of -2.01 percentage points. The year's high was 15.78% on 29 Mar 2019 and its low 0.58% on 13 Dec 2019, averaging 4.40% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.01 days on 15 May 2019. Full history: TENAX THERAPEUTICS, INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2019 in figures
- Start of year
- 2.93% (15 Jan 2019)
- End of year
- 0.92% (31 Dec 2019)
- Change
- -2.01 pp
- High
- 15.78% (29 Mar 2019)
- Low
- 0.58% (13 Dec 2019)
- Average
- 4.40%
- Highest days to cover
- 5.01 (15 May 2019)
- SEC filings marked
- 4
Every report in 2019
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2019 | 2.93% | 1.00 | |
| 31 Jan 2019 | 1.26% | 1.00 | |
| 29 Mar 2019 | 15.78% | 1.00 | |
| 15 Apr 2019 | 14.52% | 2.05 | 10-K filed |
| 30 Apr 2019 | 13.07% | 4.70 | |
| 15 May 2019 | 12.23% | 5.01 | 10-Q filed |
| 31 May 2019 | 4.91% | 2.50 | |
| 14 Jun 2019 | 4.45% | 1.94 | |
| 28 Jun 2019 | 4.32% | 2.86 | |
| 15 Jul 2019 | 3.46% | 4.14 | |
| 31 Jul 2019 | 2.45% | 1.75 | |
| 15 Aug 2019 | 2.28% | 2.65 | 10-Q filed |
| 30 Aug 2019 | 2.69% | 1.05 | |
| 13 Sep 2019 | 2.03% | 2.44 | |
| 30 Sep 2019 | 1.49% | 3.49 | |
| 15 Oct 2019 | 1.00% | 2.65 | |
| 31 Oct 2019 | 0.85% | 1.26 | |
| 15 Nov 2019 | 0.63% | 1.22 | 10-Q filed |
| 29 Nov 2019 | 0.63% | 1.72 | |
| 13 Dec 2019 | 0.58% | 2.84 | |
| 31 Dec 2019 | 0.92% | 1.18 |
See also: TENAX THERAPEUTICS, INC.'s full history · most shorted US stocks of 2019 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.